Kidney: TKI-tyrosine kinase inhibitor (TKI) sunitinib as first line therapy for metastatic renal cell cancer suggested (CCRCC) and the mTOR inhibitor, temsirolimus, CCRCC risk patients after remarkable results from two Phase III studies. Article posted in August 2006 ..

  • Kidney: TKI-tyrosine kinase inhibitor (TKI) sunitinib as first line therapy for metastatic renal cell cancer suggested (CCRCC) and the mTOR inhibitor, temsirolimus, CCRCC risk patients after remarkable results from two Phase III studies. Article posted in August 2006 ..